Stock of the Day

July 12, 2021

Danaher (DHR)

$231.52
+$6.83 (+3.0%)
Market Cap: $157.95B

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Danaher Bull Case

Here are some ways that investors could benefit from investing in Danaher Co.:

  • Danaher Co. has established a strategic collaboration with NVIDIA to integrate accelerated computing and AI technologies into its scientific instruments and laboratory automation, a move intended to advance autonomous science and accelerate drug discovery, potentially supporting long-term growth in its life-sciences businesses.
  • The company recently reported strong financial performance for the quarter ended July 20th, posting earnings per share of $1.94, which beat analyst consensus estimates of $1.85, while revenue of $6.26 billion also exceeded expectations and grew 5.5% year-over-year.
  • Danaher Co. is currently trading at $231.52, a price that reflects a significant recovery from its 52-week low of $160.93 and positions the stock near its 52-week high of $242.80, indicating strong recent momentum and investor confidence.
  • Institutional investors have shown renewed interest in the stock, with multiple firms such as Turtle Creek Wealth Advisors LLC and Mainsail Asset Management LLC significantly increasing their positions or initiating new stakes in the third quarter, suggesting broader market validation of the company's value.
  • Wall Street analysts maintain a "Moderate Buy" consensus rating with a price target of $235.41, and recent upgrades from firms like Barclays and Royal Bank of Canada, which raised their price targets to $255.00 and $250.00 respectively, indicate continued bullish sentiment among professional investors.

Danaher Bear Case

Investors should be bearish about investing in Danaher Co. for these reasons:

  • The stock carries a high valuation with a price-to-earnings ratio of 41.12, which may limit upside potential if earnings growth does not accelerate to justify the premium price relative to its peers.
  • Danaher Co. offers a relatively low dividend yield of 0.72%, which may be insufficient to attract income-focused investors seeking higher cash returns compared to other sectors or companies with more generous payout ratios.
  • Recent insider activity includes sales by executives such as Gregory M. Milosevich and Teri List, with Milosevich selling 1,320 shares in February 2026 and List selling 3,298 shares in November 2025, which some investors may interpret as a lack of confidence in near-term stock appreciation.
  • The company's debt-to-equity ratio stands at 0.48, indicating a moderate level of leverage that could constrain financial flexibility or increase risk if interest rates remain elevated or economic conditions deteriorate.
  • Despite recent gains, the stock's beta of 0.76 suggests it may underperform the broader market during significant bull runs, potentially limiting capital appreciation for investors seeking high-growth exposure.
← Previous Stock of the DayNext Stock of the Day →

Recent News